Nature Reviews Drug Discovery
BCG's Dirk Calcoen, Laura Elias, and Milton Yu wrote an article for Nature Reviews Drug Discovery exploring the unique complexities that biopharma companies face in balancing the substantial investment required to develop breakthrough therapies in HCV, Alzheimer disease, and MRSA with the growing constraints on society's ability—and willingness—to pay for such innovations.
